MedTrace Logo

Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia

NCT03768713 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2021-10-07

No results posted yet for this study

Summary

This study aims to evaluate the effect of Suvorexant on sympathetic nerve activity and baroreflex function in subject with chronic insomnia. The investigator's central hypothesis is that Suvorexant will reduce sympathetic nerve activity and improve baroreflex function when compared to placebo.

Conditions

  • Chronic Insomnia

Interventions

DRUG

Suvorexant

Insomnia subjects will take a nightly pill of 20 mg Suvorexant for eight weeks.

DRUG

Placebo

Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.

Sponsors & Collaborators

  • University of Chicago

    collaborator OTHER

  • Montana State University

    lead OTHER

Principal Investigators

  • Jason Carter, PhD · Montana State University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-18
Primary Completion
2022-12-31
Completion
2023-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03768713 on ClinicalTrials.gov